[Follow-up of benign gynecologic diseases in patients treated with tamoxifen for breast cancer].
To explore the pattern of benign gynecologic diseases in patients treated with tamoxifen for breast cancer. A total of 163 cases with breast cancer were followed up by gynecologists. The incidence rates of several benign gynecologic conditions were determined and were compared among women receiving tamoxifen and those not taking it. For a follow-up of 12-96 months, the incidence rates of leiomyomas requiring therapy was 9.20%. Compared with women not taking tamoxifen, the patients taking tamoxifen had a lower incidence rate of leiomyomas (17.59% vs 32.72%) (P < 0.05), the menopausal women taking tamoxifen had a greater incidence of endometrial lesions (P < 0.05) and the premenopausal women taking tamoxifen had a greater incidence of ovarian cysts (P < 0.05). Tamoxifen is a high risk factor for an increased risk of endometrial lesions for menopausal women and ovarian cysts for premenopausal women. But it acts as a protective factor for decreasing the incidence rate of leiomyomas.